$MLTX
MoonLake Immunotherapeutics Stock $mltx

$mltx Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000182158622000006 Filed on August 12, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.252M	$5.687M	$2.224M
YoY Change	3845.0%
% of Gross Profit
Research & Development	$11.40M	$10.25M	$4.990M
YoY Change	-61.83%
% of Gross Profit
Depreciation & Amortization	$5.780K	$2.488K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$17.65M	$2.712M	$2.224M
YoY Change	-45.99%	2781.2%	2107.48%
Operating Profit	-$17.65M	-$15.94M
YoY Change	-45.99%
Interest Expense		$7.770K	$2.260K
YoY Change			-84.85%
% of Operating Profit
Other Income/Expense, Net	$245.1K	$69.51K	-$40.00K
YoY Change	-6584.92%
Pretax Income	-$17.41M	-$2.704M	-$2.222M
YoY Change	11327.2%	3444.0%	2488.55%
Income Tax	$9.282K	$7.330K	$0.00
% Of Pretax Income
Net Earnings	-$12.12M	-$15.88M	-$2.222M
YoY Change	-62.92%	4415.6%	2488.55%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.34	-$3.17
Diluted Earnings Per Share	-$0.34	-$183.3K	-$150.1K
COMMON SHARES
Basic Shares Outstanding	35.20M shares	5.014M shares
Diluted Shares Outstanding	35.20M shares	5.014M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$92.71M	$23.34K	$666.8K
YoY Change	8345.65%	-98.01%	-50.09%
Cash & Equivalents	$92.71M	$8.834M	$8.039M
Short-Term Investments			$0.00
Other Short-Term Assets	$5.113M	$101.1M	$126.9K
YoY Change	2089.41%	34819.01%	-55.16%
Inventory
Prepaid Expenses	$5.113M		$1.449M
Receivables
Other Receivables	$557.0K		$148.8K
Total Short-Term Assets	$98.38M	$116.2M	$9.637M
YoY Change	7290.04%	7857.8%	495.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$55.97K	$100.0K	$45.74K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$115.1M	$115.0M
YoY Change		0.02%	0.02%
Other Assets
YoY Change
Total Long-Term Assets	$55.97K	$115.1M	$45.74K
YoY Change	-99.95%	0.02%	-99.96%
TOTAL ASSETS
Total Short-Term Assets	$98.38M	$116.2M	$9.637M
Total Long-Term Assets	$55.97K	$115.1M	$45.74K
Total Assets	$98.43M	$231.2M	$9.682M
YoY Change	-15.41%	98.48%	-91.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$661.9K	$3.400M
YoY Change
Accrued Expenses	$3.066M	$5.798M	$3.870M
YoY Change	3306.61%	9563.25%	5666.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$150.0K	$15.00M
YoY Change			25735.34%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.857M	$202.8M	$21.09M
YoY Change	4185.57%	337883.77%	16745.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$18.59K	$4.025M	$4.025M
YoY Change	-99.54%	0.0%	0.0%
Total Long-Term Liabilities	$18.59K	$4.025M	$239.9K
YoY Change	-99.54%	0.0%	-94.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.857M	$202.8M	$21.09M
Total Long-Term Liabilities	$18.59K	$4.025M	$239.9K
Total Liabilities	$3.876M	$206.8M	$21.33M
YoY Change	-5.82%	4962.8%	413.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.68M		-$53.64M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00		$6.202K
YoY Change
Treasury Stock Shares			1.943M shares
Shareholders Equity	$63.51M	$24.40M	-$11.65M
YoY Change
Total Liabilities & Shareholders Equity	$98.43M	$231.2M	$9.682M
YoY Change	-15.41%	98.48%	-91.7%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$12.12M	-$15.88M	-$2.222M
YoY Change	-62.92%	4415.6%	2488.55%
Depreciation, Depletion And Amortization	$5.780K	$2.488K	$0.00
YoY Change
Cash From Operating Activities	-$34.15M	-$793.5K	-$362.0K
YoY Change	47092.07%	636.04%	14.29%
INVESTING ACTIVITIES
Capital Expenditures	-$16.01K	$16.01K	$20.00K
YoY Change	-180.05%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$16.01K	-$16.01K	-$20.00K
YoY Change	-19.95%		-99.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$80.84M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	119.5M	150.0K	0.000
YoY Change		-358.35%	-100.0%
NET CHANGE
Cash From Operating Activities	-34.15M	-793.5K	-362.0K
Cash From Investing Activities	-16.01K	-$16.01K	-20.00K
Cash From Financing Activities	119.5M	150.0K	0.000
Net Change In Cash	85.37M	-643.5K	-362.0K
YoY Change	-118063.29%	287.95%	-127.09%
FREE CASH FLOW
Cash From Operating Activities	-$34.15M	-$793.5K	-$362.0K
Capital Expenditures	-$16.01K	$16.01K	$20.00K
Free Cash Flow	-$34.14M	-$809.5K	-$382.0K
YoY Change	36856.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001821586
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39630
	dei	Entity Registrant Name EntityRegistrantName	MOONLAKE IMMUNOTHERAPEUTICS
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Dorfstrasse 29
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Zug
	dei	Entity Address Country EntityAddressCountry	CH
	dei	City Area Code CityAreaCode	41
	dei	Local Phone Number LocalPhoneNumber	415108022
	dei	Security12b Title Security12bTitle	Class A ordinary share, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	MLTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	us-gaap	Cash Cash	92707931	usd
CY2021Q4	us-gaap	Cash Cash	8038845	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	557048	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	148774	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5112702	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1449096	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	98377681	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	9636715	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55971	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45739	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	55971	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	45739	usd
CY2022Q2	us-gaap	Assets Assets	98433652	usd
CY2021Q4	us-gaap	Assets Assets	9682454	usd
CY2022Q2	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	791061	usd
CY2021Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	1569290	usd
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	15000000	usd
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3065951	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4518311	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3857012	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21087601	usd
CY2022Q2	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	18588	usd
CY2021Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	239860	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18588	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	239860	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3875600	usd
CY2021Q4	us-gaap	Liabilities Liabilities	21327461	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1942837	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	6202	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	122053558	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42061984	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58677824	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53643615	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	133723	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-168177	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	63514728	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-11645007	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	31043324	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	0	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	94558052	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11645007	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98433652	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9682454	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11400541	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29867218	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21655404	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29867218	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6251636	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2814781	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11939088	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3165236	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	17652177	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	32681999	usd
	us-gaap	Operating Expenses OperatingExpenses	33594492	usd
	us-gaap	Operating Expenses OperatingExpenses	33032454	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17652177	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-32681999	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33594492	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33032454	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	245130	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3780	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	314635	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4998	usd
CY2022Q2	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-17407047	usd
CY2021Q2	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-32685779	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-33279857	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-33037452	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9282	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16614	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-17416329	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-32685779	usd
	us-gaap	Profit Loss ProfitLoss	-33296471	usd
	us-gaap	Profit Loss ProfitLoss	-33037452	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-12120719	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-32685779	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22754974	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33037452	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5295610	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10541497	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	101597	usd
CY2021Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	367866	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-1000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	101597	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	367866	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-17314732	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-32686779	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-32928605	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-33038452	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12052683	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32686779	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22508629	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33038452	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-5262049	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-10419976	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106508	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-351673	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-245165	usd
CY2021Q2	mnlk	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	4851000	usd
CY2021Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1250365	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	27659237	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-32685779	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	828658	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11645007	usd
CY2022Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1992662	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-15880142	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	266269	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-25266218	usd
CY2022Q2	mnlk	Noncontrolling Interest Decrease From Reverse Recapitalization NoncontrollingInterestDecreaseFromReverseRecapitalization	0	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1578	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	134653201	usd
CY2022Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2484223	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-17416329	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	101597	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	94558052	usd
	us-gaap	Profit Loss ProfitLoss	-33296471	usd
	us-gaap	Profit Loss ProfitLoss	-33037452	usd
	us-gaap	Depreciation Depreciation	5776	usd
	us-gaap	Depreciation Depreciation	213	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4473094	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1250365	usd
	mnlk	Research And Development In Process Share Based Portion ResearchAndDevelopmentInProcessShareBasedPortion	0	usd
	mnlk	Research And Development In Process Share Based Portion ResearchAndDevelopmentInProcessShareBasedPortion	4851000	usd
	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	151380	usd
	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	4645	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-20913	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	408274	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	10778	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3663606	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	45318	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-778229	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	549268	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1450930	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	733484	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34946347	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25704573	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16008	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20683	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16008	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20683	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	106508	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	27659237	usd
	mnlk	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	134646009	usd
	mnlk	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	0	usd
	mnlk	Proceeds From Contribution From Par Value Of Common Stock ProceedsFromContributionFromParValueOfCommonStock	42935	usd
	mnlk	Proceeds From Contribution From Par Value Of Common Stock ProceedsFromContributionFromParValueOfCommonStock	0	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	15000000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119688944	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27765745	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-57502	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	84669087	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2040489	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8038845	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92707932	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2040489	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2580	usd
CY2022Q2	mnlk	Reverse Recapitalization Accrued Expenses ReverseRecapitalizationAccruedExpenses	5798000	usd
CY2022Q2	mnlk	Reverse Recapitalization Deferred Initial Public Offering Underwriting Fees ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees	4025000	usd
CY2022Q2	mnlk	Reverse Recapitalization Other Transaction Expenses ReverseRecapitalizationOtherTransactionExpenses	5697000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134689000	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52701111	shares
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	15000000.0	usd
CY2022Q2	mnlk	Investments Acquired Through Reverse Recapitalization InvestmentsAcquiredThroughReverseRecapitalization	115051000	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	80842000	usd
CY2022Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	116000000	usd
CY2022Q2	mnlk	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	15520000	usd
CY2022Q2	mnlk	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	33.638698
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining whether the in-process research and development expenditure (“IPR&D”) has an alternative future use;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the fair value of the portion of the aggregate purchase price relating to its own shares in connection with the acquisition of the in-license agreement;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining assumptions used in determining the fair value of share-based compensation; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a large financial institution which, at times, may exceed the CHF 100,000 deposit protection limit. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held.
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	100000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	340553	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	268292	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-3493	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-4690	usd
CY2022Q2	us-gaap	Cash Cash	92700000	usd
	us-gaap	Profit Loss ProfitLoss	-33300000	usd
CY2022Q2	mnlk	Current Assets In Excess Of Current Liabilities CurrentAssetsInExcessOfCurrentLiabilities	94500000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	2714439	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	23141	usd
CY2022Q2	mnlk	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	2236442	usd
CY2021Q4	mnlk	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	547586	usd
CY2022Q2	mnlk	Prepaid Supply And Manufacturing PrepaidSupplyAndManufacturing	83559	usd
CY2021Q4	mnlk	Prepaid Supply And Manufacturing PrepaidSupplyAndManufacturing	750622	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	78262	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	127747	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5112702	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1449096	usd
CY2022Q2	mnlk	Supply And Manufacturing Fees Payable Current SupplyAndManufacturingFeesPayableCurrent	401991	usd
CY2021Q4	mnlk	Supply And Manufacturing Fees Payable Current SupplyAndManufacturingFeesPayableCurrent	183298	usd
CY2022Q2	mnlk	Accrued Legal And Intellectual Property Advisory Fees Payable Current AccruedLegalAndIntellectualPropertyAdvisoryFeesPayableCurrent	246750	usd
CY2021Q4	mnlk	Accrued Legal And Intellectual Property Advisory Fees Payable Current AccruedLegalAndIntellectualPropertyAdvisoryFeesPayableCurrent	1233070	usd
CY2022Q2	mnlk	Other Accrued Consulting And Advisory Fees Current OtherAccruedConsultingAndAdvisoryFeesCurrent	78514	usd
CY2021Q4	mnlk	Other Accrued Consulting And Advisory Fees Current OtherAccruedConsultingAndAdvisoryFeesCurrent	71938	usd
CY2022Q2	mnlk	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	13130	usd
CY2021Q4	mnlk	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	50088	usd
CY2022Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	50676	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	30896	usd
CY2022Q2	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	791061	usd
CY2021Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	1569290	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1559202	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	63922	usd
CY2022Q2	mnlk	Accrued License Fees Current AccruedLicenseFeesCurrent	636217	usd
CY2021Q4	mnlk	Accrued License Fees Current AccruedLicenseFeesCurrent	2055687	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	530714	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1419137	usd
CY2022Q2	mnlk	Accrued Consulting And Other Fees Current AccruedConsultingAndOtherFeesCurrent	277540	usd
CY2021Q4	mnlk	Accrued Consulting And Other Fees Current AccruedConsultingAndOtherFeesCurrent	49211	usd
CY2022Q2	mnlk	Accrued Legal Fees Current AccruedLegalFeesCurrent	62278	usd
CY2021Q4	mnlk	Accrued Legal Fees Current AccruedLegalFeesCurrent	930354	usd
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3065951	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4518311	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1600000	usd
CY2022Q2	mnlk	Taxes Payable Stamp Duty Fees Current TaxesPayableStampDutyFeesCurrent	1300000	usd
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	2533	usd
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	0	usd
CY2022Q2	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	3771	usd
CY2022Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	109607	usd
CY2021Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	11423	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	225965	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	11423	usd
CY2022Q2	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	1229	usd
CY2021Q2	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	0	usd
CY2021Q2	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	0	usd
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	7775	usd
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	0	usd
CY2022Q2	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-442	usd
CY2021Q4	mnlk	Shares Authorized SharesAuthorized	36000000	shares
CY2021Q2	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	0	usd
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-910	usd
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	0	usd
CY2022Q2	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	107507	usd
CY2021Q2	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	11423	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	221633	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	11423	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	70137	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	66197	chf
CY2021Q4	us-gaap	Shares Issued SharesIssued	33099402	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	1177354	shares
CY2022Q1	mnlk	Shares Authorized SharesAuthorized	36000000	shares
CY2022Q1	us-gaap	Shares Issued SharesIssued	34276756	shares
CY2022Q2	mnlk	Stock Authorized During Period Shares Acquisitions StockAuthorizedDuringPeriodSharesAcquisitions	600000000	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	18424355	shares
CY2022Q2	mnlk	Stock Authorized During Period Shares Conversion Of Convertible Securities StockAuthorizedDuringPeriodSharesConversionOfConvertibleSecurities	-36000000	shares
CY2022Q2	mnlk	Shares Authorized SharesAuthorized	600000000	shares
CY2022Q2	us-gaap	Shares Issued SharesIssued	52701111	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-12120719	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-32685779	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22754974	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33037452	usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35201713	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35201713	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11278991	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11278991	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20191072	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20191072	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15632208	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15632208	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.90
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2500000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4500000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2484223	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1250365	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4473094	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1250365	usd
	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
CY2022Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.001
CY2021Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.000
CY2022Q2	mnlk	Unrecognized Commitments And Contingencies UnrecognizedCommitmentsAndContingencies	44800000	usd
	mnlk	Contract With Customer Percentage Due Upon Initiation Of Next Clinical Trial ContractWithCustomerPercentageDueUponInitiationOfNextClinicalTrial	0.01
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	340553	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	268292	usd

Files In Submission

Name	View Source	Status
mnlk-20220630_cal.xml	Edgar Link	unprocessable
0001821586-22-000006-index-headers.html	Edgar Link	pending
0001821586-22-000006-index.html	Edgar Link	pending
0001821586-22-000006.txt	Edgar Link	pending
0001821586-22-000006-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mltx_2022q2xex311dasilva.htm	Edgar Link	pending
mltx_2022q2xex312bodenstedt.htm	Edgar Link	pending
mltx_2022q2xex321dasilva.htm	Edgar Link	pending
mltx_2022q2xex322bodenstedt.htm	Edgar Link	pending
mnlk-20220630.htm	Edgar Link	pending
mnlk-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
mnlk-20220630_def.xml	Edgar Link	unprocessable
mnlk-20220630_lab.xml	Edgar Link	unprocessable
mnlk-20220630_pre.xml	Edgar Link	unprocessable
mnlk-20220630_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MLTX
MoonLake Immunotherapeutics Stock $mltx

2022 Q2 Form 10-Q Financial Statement

#000182158622000006 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLTX MoonLake Immunotherapeutics Stock $mltx

2022 Q2 Form 10-Q Financial Statement

#000182158622000006 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLTX
MoonLake Immunotherapeutics Stock $mltx